Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Voydeya (danicopan) is an oral complement factor D inhibitor approved by the FDA as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Voydeya inhibits complement factor D, targeting the alternative complement pathway responsible for extravascular hemolysis that can persist in some PNH patients despite treatment with a C5 complement inhibitor like ravulizumab or eculizumab. By addressing this additional pathway, Voydeya helps further reduce red blood cell destruction.
Voydeya is intended for PNH patients who continue to experience clinically significant extravascular hemolysis despite ongoing treatment with a C5 inhibitor, used as an add-on rather than a standalone therapy.
The recommended starting dose of Voydeya is 150 mg orally three times daily, which may be increased to 200 mg three times daily based on clinical response, always used alongside ravulizumab or eculizumab.
Boxed Warning — Voydeya: Voydeya increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. Patients must complete or update meningococcal and other relevant vaccinations at least two weeks before the first dose of Voydeya, unless the risks of delaying treatment outweigh the risk of infection.
Patients who have not been vaccinated should receive prophylactic antibacterial treatment until two weeks after vaccination, per current guidelines, given the increased infection risk.
Liver enzyme elevations have been observed. Liver function should be monitored periodically during treatment.
Increases in cholesterol levels have been reported. Periodic lipid monitoring is recommended.
Patients should be monitored for signs of hemolysis for at least two weeks after discontinuing Voydeya.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Voydeya is manufactured and marketed by Alexion Pharmaceuticals, an AstraZeneca Rare Disease company. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist confirming PNH diagnosis and ongoing treatment with ravulizumab or eculizumab. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved add-on therapy for PNH with extravascular hemolysis, Voydeya is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Voydeya directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Voydeya should be stored at 20°C to 25°C, with excursions permitted between 15°C and 30°C, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Voydeya through NPP's regulated import pathway, with hematology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology care coordination and documentation for Voydeya access.
Delhi's major hospitals assist patients with prescription support and documentation for Voydeya.
Bangalore's specialist network offers access coordination for eligible PNH patients seeking Voydeya.
Chennai-based hematology specialists coordinate Voydeya access alongside comprehensive PNH care.
Hyderabad's care institutions support patients pursuing Voydeya therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Voydeya.
Pune-based specialists assist with prescription support and Voydeya treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Voydeya.
Kochi's specialist units assist patients with the documentation needed for Voydeya access.
Chandigarh's care centers support Voydeya treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Voydeya access process.
Lucknow-based centers assist patients pursuing Voydeya therapy.
Bhubaneswar's institutions support access to Voydeya for eligible patients.
Guwahati's specialists help coordinate Voydeya access for patients across the Northeast.
Patients in other cities across India can also access Voydeya through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
